$VCKA News
Last published 4y ago
- 4y agoSRNEVCKAScilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business CombinationGlobeNewswireSEC declared Effectiveness of Vickers's registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured NotesGlobeNewswirePALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment o
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)GlobeNewswireSP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to s
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North AfricaGlobeNewswirePALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8%GlobeNewswire30 million lives now covered by one of the largest national PBMs Continue to work with this PBM to access an additional 20 million lives The team continues to work with the national PBM's and health plans to improve access further during 2022 with a g
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.GlobeNewswireAncora Medical Inc. ("Ancora") is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-op
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of DirectorsGlobeNewswirePALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused o
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.GlobeNewswireGloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements inc
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured NotesGlobeNewswireSAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical com
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plansGlobeNewswireEarlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered by managed health care plans representing approximate
- 4y agoSRNEVCKAScilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back PainGlobeNewswireDosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination between Scilex and VickersGlobeNewswirePALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (NASDAQ:SRNE, "Sorrento"))) and Vickers Vantage
- 4y agoSRNEVCKAScilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for FibromyalgiaGlobeNewswireSP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care
- 4y agoSRNEVCKAScilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual MeetingGlobeNewswireSP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its pr
- 4y agoSRNEVCKAScilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)GlobeNewswireSAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceut
- 4y agoSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.GlobeNewswirePALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused
- 4y agoSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And PharmaciesGlobeNewswirePALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused
- 4y agoSRNEVCKADr. Henry Ji, Sorrento Therapeutics' Chairman and CEO and Scilex Holding Company's Executive Chairman, to Present at the B. Riley Securities' 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)GlobeNewswireSAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company ("Scilex"), wil
- 4y agoSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura HamillGlobeNewswirePALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused
- 4y agoVCKAVCKAUVICKERS VANTAGE CORP. I EXTENDS TIME TO COMPLETE BUSINESS COMBINATIONGlobeNewswireNEW YORK, NY, April 11, 2022 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (NASDAQ:VCKAU, VCKA, VCKAW))) ("Vickers" or the "Company"), a Cayman Islands exempted company, announced today that it has further extended the time it has to consummate an ini
- 4y agoSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022GlobeNewswireZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, Calif., April 04, 2022 (GLO
- 4y agoRILYSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp IGlobeNewswirePALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercial
- 4y agoBCACRNERSUMRVCKAMoore Kuehn Encourages VCKA, RNER, BCAC, and SUMR Investors to Contact Law FirmPR NewswireNEW YORK, March 24, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 4y agoSRNEVCKAScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market OpportunityGlobeNewswireSP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affect
- 4y agoSRNEVCKAScilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. IGlobeNewswireCombined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage C
- 4y agoVCKAVICKERS VANTAGE CORP. I EXTENDS TIME TO COMPLETE BUSINESS COMBINATIONGlobeNewswireNEW YORK, NY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (Nasdaq: VCKAU, VCKA, VCKAW) ("Vickers" or the "Company"), a Cayman Islands exempted company, announced today that it has extended the time it has to consummate an initial busine
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class TherapyGlobeNewswireScilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, cort
- 4y agoSRNEVCKAScilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) ("SPAC") Enter into Letter of Intent for Proposed Business CombinationGlobeNewswireScilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), and Vickers Vantage Corp I (NASDAQ:VCKA) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity v
- 5y agoVCKAVICKERS VANTAGE CORP. I RECEIVES NASDAQ NOTIFICATION OF NON-COMPLIANCE WITH LISTING RULESGlobeNewswireSINGAPORE, June 01, 2021 (GLOBE NEWSWIRE) -- VICKERS VANTAGE CORP. I (NASDAQ:VCKA) ("Vickers" or the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization o
- 5y agoVCKAVickers Vantage Corp. I Announces the Separate Trading of its Common Stock and Warrants, Commencing March 3 2021GlobeNewswireNEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (NASDAQ: VCKAU) (the “Company”) announced that, commencing 3rd March 2021 holders of the units sold in the Company’s initial...
- 5y agoVCKAVickers Vantage Corp. I Announces Closing of $138,000,000 Initial Public OfferingGlobeNewswireNEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (the “Company”) announced today that it closed its initial public offering of 13,800,000 units, including the full 1,800,000 units...
- 5y agoVCKAVickers Vantage Corp. I Announces Pricing of Upsized $120,000,000 Initial Public OfferingGlobeNewswireNEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (the “Company”) announced today that it priced its initial public offering of 12,000,000 units at $10.00 per unit. The units will...